证券代码：300181 证券简称：佐力药业 编号：2023-010 浙江佐力药业股份有限公司 | --- | --- | |--------------|---------------------------| | 投资者关系活 | □特定对象调研 □分析师会议 | | 动类别 | □媒体采访 □业绩说明会 | □新闻发布会 □路演活动 现场参观 其他 （线上会议） 参与单位名称 2023 年 7 月 6 日 14:30-15:30 景顺长城：陈婧琳、王玉； 及人员姓名 光大证券：黄素青。 2023 年 7 月 6 日 16:00-16:35 博时基金：梁起飞、王诗瑶、 刘宁、柴文超；西南证券：钱彦君。 2023 年 7 月 7 日 10:30-11:30 中融基金：甘传琦、刘柏川。 时间 2023 年 7 月 6 日 14:30-15:30；16:00-16:35 2023 年 7 月 7 日 10:30-11:30 地点 线上会议、公司会议室 上市公司接待 人员姓名 董事、常务副总经理兼董事会秘书：冯国富 问题一：乌灵系列二季度的销售情况如何？ 投资者关系活 答：乌灵胶囊和灵泽片二季度整体销售情况还不错， ...

证券代码：300181 证券简称：佐力药业 编号：2023-009 浙江佐力药业股份有限公司 | --- | --- | |--------------|---------------------------| | 投资者关系活 | □特定对象调研 □分析师会议 | | 动类别 | □媒体采访 □业绩说明会 | □新闻发布会 □路演活动 □现场参观 其他 （线上会议） 参与单位名称 大成基金: 朱亭霖、王敏杰 及人员姓名 光大证券: 黄素青 ; brilliance capital:石林、邢庭志、 王珏帆 时间 2023 年 6 月 12 日 14:00-15:00 2023 年 6 月 12 日 15:00-16:00 地点 线上会议 上市公司接待 人员姓名 董事、常务副总经理兼董事会秘书：冯国富 问题一：公司在集采前后的成本费用的结构是怎么变化的？ 答：公司主要产品原本就有原材料成本可控的优势，产品毛 利率较高。进入集采后，公司从营销端和生产端两个方面来 投资者关系活 降低成本费用，消化集采价格对利润的影响。在营销端，集采 动主要内容介 中标品种对于开发医院有优势，在增加医院覆盖数量提升产品销 绍 量的同 ...

证券代码：300181 证券简称：佐力药业 编号：2023-008 浙江佐力药业股份有限公司 | --- | --- | --- | |-------------------|-----------------------|-------------| | 投 资 者 关 系 活 | ☑特定对象调研 | □分析师会议 | | 动类别 | □媒体采访 □业绩说明会 | | □新闻发布会 □路演活动 ☑现场参观 其他 参 与 单 位 名 称 光大证券：黄素青；西南证券：钱彦君；华安证券：李昌幸、 及人员姓名(排 肖又通；东方财富证券：何玮；兴业证券：董晓洁；brilliance 名不分先后） capital：石林、王珏帆；泰康资产：马步云；兴业基金：张 诗悦；中海基金：彭天阳；弘尚资产：王若曦；趣时投资： 王晓东；汇添富基金：韩超；光保基金：张翔宇；招商基金： 任绍聪；六禾投资：陈信余；翼融资产：宋进；大成基金： 张烨；证券时报：李欣；象树资产：沈琪；开源证券：蔡明 子、古意涵；兴全基金：叶飞。 时间 2023 年 5 月 26 日 10:00-11:30 地点 公司会议室 上 市 公 司 接 待 人员姓名 董事 ...

证券代码：300181 证券简称：佐力药业 编号：2023-007 浙江佐力药业股份有限公司 | --- | --- | |----------------|------------| | 投资者关系活动 | | | 类别 | 业绩说明会 | □新闻发布会 □路演活动 □现场参观 其他 （券商策略会） 参与单位名称及 1、公司于 2023 年 5 月 10 日前往上海，参加由东吴证券、国 人员姓名 海证券、国盛证券组织的上市公司交流会，大成基金、富国基 金、南方基金、景顺长城基金等投资者参与。部分名单详见附 件清单。 重要提示：参会人员名单由组织机构提供并经整理后展示。公 司无法保证所有参会人员及其单位名称的完整性和准确性，请 投资者注意。 2、线上参与公司 2022 年度网上业绩说明会的投资者 时间 2023 年 5 月 10 日 10:00-18:00 2023 年 5 月 12 日 15:00-17:00 地点 上海、公司会议室（约调研"佐力药业投资者关系"微信小程 序） 2023 年 5 月 10 日： 董事、常务副总经理兼董事会秘书：冯国富 上市公司接待人 2023 年 5 月 12 日： 员姓名 ...

浙江佐力药业股份有限公司（以下简称"公司"）已于2023年4月26日在巨 潮资讯网（http://www.cninfo.com.cn）披露了《2022年年度报告》及《2022年 年度报告摘要》。 为便于广大投资者更深入全面地了解公司发展战略、生产经营等情况，公司 定于2023年5月12日（星期五）下午15:00-17:00在"佐力药业投资者关系"小 程序举行2022年度网上业绩说明会。本次网上业绩说明会将采用网络远程的方 式举行，投资者可登陆"佐力药业投资者关系"小程序参与互动交流。为广泛听 取投资者的意见和建议，提前向投资者征集问题，提问通道自发出公告之日起开 放。 参与方式一：在微信小程序中搜索"佐力药业投资者关系"； 参与方式二：微信扫一扫以下二维码： 投资者依据提示，授权登入"佐力药业投资者关系"小程序，即可参与交流。 出席本次网上说明会的人员有：董事长俞有强先生，总经理汪涛先生，董事、 常务副总经理兼董事会秘书冯国富先生，副总经理、财务总监叶利女士，独立董 证券代码：300181 证券简称：佐力药业 公告编号：2023-024 浙江佐力药业股份有限公司 关于举行2022年度网上业绩说明会的公告 本公 ...

Financial Performance - The company's operating revenue for 2022 was CNY 1,805,155,365.79, representing a 23.86% increase compared to CNY 1,457,396,066.42 in 2021[17]. - The net profit attributable to shareholders for 2022 was CNY 273,006,652.56, a 52.17% increase from CNY 179,408,091.21 in the previous year[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 264,713,695.17, up 52.94% from CNY 173,082,925.27 in 2021[17]. - The basic earnings per share for 2022 was CNY 0.45, reflecting a 55.17% increase from CNY 0.29 in 2021[17]. - The total assets at the end of 2022 amounted to CNY 3,639,117,963.07, a 32.40% increase from CNY 2,748,532,182.07 at the end of 2021[17]. - The net assets attributable to shareholders at the end of 2022 were CNY 2,703,749,664.26, which is a 46.62% increase from CNY 1,844,064,465.20 in 2021[17]. - The cash flow from operating activities for 2022 was CNY 318,591,105.19, an increase of 26.53% compared to CNY 251,798,511.89 in 2021[17]. - The total profit for the year was CNY 324.12 million, representing a 45.80% increase compared to the previous year[47]. - The company reported quarterly revenues of CNY 439,416,764.79, CNY 455,531,334.16, CNY 449,454,503.18, and CNY 460,752,763.66 for Q1, Q2, Q3, and Q4 respectively[19]. Market Position and Growth - The company is positioned in the Chinese medicine manufacturing industry, which is expected to grow significantly, with the market size projected to reach approximately 481.8 billion CNY by 2023[29]. - The government has introduced multiple supportive policies for the traditional Chinese medicine industry, enhancing its development prospects[27]. - The market for traditional Chinese medicine is expected to continue expanding due to increasing healthcare awareness and aging population trends[28]. - The company ranked 56th in the "2021 Top 100 Chinese Traditional Medicine Enterprises" list by Minai Network and 35th in the "2022 Comprehensive Competitiveness of Chinese Traditional Medicine Enterprises" list[30]. - The company is focusing on high-quality development in the traditional Chinese medicine sector, aligning with national health strategies and policies[28]. Product Development and Innovation - The company's main products include Wuling Capsule, Bailing Tablets, Lingze Tablets, and Linglianhua Granules, focusing on traditional Chinese medicine[33]. - Wuling Capsule is recognized as a national Class I new drug, demonstrating its clinical safety and efficacy in improving sleep and alleviating anxiety[34]. - Lingze Tablets, targeting benign prostatic hyperplasia, were included in three clinical guidelines during the reporting period, highlighting their therapeutic significance[35]. - Bailing Tablets, derived from fermented Cordyceps, are indicated for chronic obstructive pulmonary disease and have shown effectiveness in improving lung function[35]. - The company has successfully developed new products and expanded its market presence, contributing to its growth and recognition in the pharmaceutical industry[30]. - The company has launched the first generic drug of Pugka Bofen Calcium Tablets in China, which is primarily used for treating constipation caused by irritable bowel syndrome[36]. - The company is actively expanding the clinical application of Pugka Bofen Calcium Tablets by submitting a clinical research application for an additional indication of diarrhea caused by irritable bowel syndrome, which has been approved and is currently in clinical trials[37]. Research and Development - The company is committed to the research and development of medicinal fungi, which is a significant area in modern traditional Chinese medicine, with a focus on products that address mental health issues[41]. - The company has made advancements in the biotechnological production of traditional Chinese medicine products, particularly through the industrialization of rare medicinal materials like Wuling[42]. - The company plans to continue investing in smart factory construction to enhance production efficiency and quality control[49]. - The company has allocated $50 million for research and development of new products in 2022, targeting a launch of at least two new products by Q4 2022[109]. - The company will increase investment in R&D, focusing on innovative drugs and new drug development, while enhancing the capabilities of its five research platforms[104]. Financial Management and Governance - The company has established a comprehensive internal control system to enhance governance and operational efficiency[115]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 816.53 million CNY[135]. - The highest remuneration was received by the Chairman, Yu Youqiang, at 104.98 million CNY, followed closely by the General Manager, Wang Tao, at 108.76 million CNY[135]. - The company has a structured remuneration management system that requires approval from the board and shareholders for compensation decisions[133]. - The company has maintained complete independence from its controlling shareholders in terms of business, personnel, assets, and finances[116]. - The company actively engages with investors through various channels, enhancing transparency and protecting minority shareholder rights[114]. Future Outlook and Strategic Plans - The company plans to raise CNY 910 million for projects including the construction and upgrade of an intelligent traditional Chinese medicine production base and a digital operation decision-making system[47]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by 2025[110]. - The company provided guidance for 2023, projecting a revenue target of 1.5 billion yuan, which would represent a 25% increase year-on-year[167]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 100 million yuan set aside for this purpose in 2022[110]. - The company is committed to building an intelligent traditional Chinese medicine production base and upgrading its production systems with advanced automation equipment[104]. Risks and Challenges - The company faces risks from industry policy changes, including adjustments to the medical insurance catalog and procurement policies, which could impact operations[105]. - The company acknowledges the risks associated with drug development, including high costs and long development cycles, which may affect market prospects[106]. - The company recognizes the risk of goodwill impairment from acquisitions and will enhance its operational planning and management capabilities to improve subsidiary performance[107].

Financial Performance - The company's revenue for Q1 2023 was CNY 495.70 million, an increase of 12.81% compared to CNY 439.42 million in the same period last year[4]. - Net profit attributable to shareholders for Q1 2023 was CNY 97.45 million, representing a growth of 41.76% from CNY 68.75 million year-on-year[4]. - Total operating revenue for Q1 2023 reached ¥495,697,829.83, an increase of 12.8% compared to ¥439,416,764.79 in Q1 2022[23]. - Net profit for Q1 2023 was ¥99,453,357.42, representing a 36.6% increase from ¥72,755,387.42 in Q1 2022[24]. - Total comprehensive income for the period was CNY 51,254,457.45, compared to a loss of CNY 139,671,939.61 in the previous period[25]. - Basic and diluted earnings per share increased to CNY 0.1389 from CNY 0.1130 year-over-year[25]. Cash Flow and Liquidity - The net cash flow from operating activities decreased by 85.99% to CNY 12.01 million, down from CNY 85.73 million in the previous year[4]. - Cash inflow from operating activities was CNY 529,472,730.86, up from CNY 439,531,004.52 in the previous period[26]. - Net cash flow from operating activities decreased to CNY 12,013,227.66 from CNY 85,732,512.56 year-over-year[26]. - Cash outflow from investing activities totaled CNY 75,105,495.75, compared to CNY 183,996,549.20 in the previous period[28]. - Net cash flow from investing activities was negative CNY 64,248,767.61, an improvement from negative CNY 120,739,205.69 year-over-year[28]. - Cash inflow from financing activities was CNY 78,000,000.00, down from CNY 177,572,000.00 in the previous period[28]. - The ending balance of cash and cash equivalents was CNY 1,009,262,229.22, compared to CNY 183,024,828.55 in the previous period[28]. - The company reported cash and cash equivalents of CNY 1,022,965,970.70 at the end of Q1 2023, down from CNY 1,082,070,763.05 at the beginning of the year[19]. Research and Development - R&D expenses for Q1 2023 amounted to CNY 18.21 million, a significant increase of 56.11% compared to CNY 11.57 million in the same period last year[9]. - Research and development expenses increased to ¥18,208,988.62 in Q1 2023, compared to ¥11,664,510.89 in Q1 2022, marking a growth of 55.9%[23]. Assets and Liabilities - The total assets at the end of Q1 2023 were CNY 3.60 billion, a slight decrease of 1.16% from CNY 3.64 billion at the end of the previous year[4]. - Total liabilities decreased to ¥785,641,351.46 in Q1 2023 from ¥879,192,754.90 in Q1 2022, a reduction of 10.6%[21]. - The company's equity attributable to shareholders increased by 1.96% to CNY 2.76 billion compared to CNY 2.70 billion at the end of the previous year[4]. - The equity attributable to shareholders of the parent company rose to ¥2,756,618,357.18 in Q1 2023, up from ¥2,703,749,664.26 in Q1 2022[21]. Inventory and Costs - The company reported a gross profit margin decrease due to increased costs, with operating costs rising by 21.37% to CNY 149.29 million[9]. - The company experienced a significant increase in inventory, which rose by 16.34% to CNY 370.92 million, primarily due to anticipated price increases in traditional Chinese medicine materials[8]. - Inventory increased to CNY 370,920,557.09 from CNY 318,826,460.84, reflecting a growth of approximately 16.3%[19]. - Total operating costs for Q1 2023 were ¥400,185,140.69, up from ¥371,390,609.52 in the same period last year, reflecting a rise of 7.3%[23]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,698[12]. - The largest shareholder, Yu Youqiang, holds 18.52% of shares, totaling 129,890,463 shares, with 97,417,847 shares pledged[12]. - The top ten shareholders include both individual and institutional investors, with UBS AG holding 1.40% of shares[13]. - The total number of preferred shareholders is zero, indicating no preferred shares outstanding[14]. - The company has not disclosed any related party transactions among the top ten shareholders[13]. Future Plans - The company plans to continue investing in long-term assets, including the "Intelligent Traditional Chinese Medicine Production Base Construction and Upgrade Project"[8]. - The company plans to continue focusing on market expansion and new product development to drive future growth[24]. Audit and Reporting - The company did not undergo an audit for the first quarter report[29]. - The report was released by the board of directors on April 24, 2023[30].